Literature DB >> 1537462

Oxidative and reductive metabolism by cytochrome P450 2E1.

D R Koop1.   

Abstract

We are constantly exposed to many potentially toxic chemicals. Most require metabolic activation to species responsible for cell injury. Although cytochrome P450 2E1 is only one of many different forms of cytochrome P450 that catalyze these reactions, it has an important role in human health as a result of being readily induced by acute and chronic alcohol ingestion. The enzyme efficiently catalyzes the low Km metabolism of compounds commonly used as solvents in industry and at home as well as components found in cigarette smoke, many of which are established carcinogens and hepatotoxins. As a result, there is the potential for increased risk to low level exposure to such chemicals while cytochrome P450 2E1 is induced. Many substrates have been identified for cytochrome P450 2E1. Of the 52 substrates for the enzyme identified in this review, the demethylation of N,N-dimethylnitrosamine and the hydroxylation of p-nitrophenol and chlorzoxazone are the most effective for monitoring the level of this enzyme. In addition to oxidative reactions, cytochrome P450 2E1 is also an efficient catalyst of reductive reactions. CCl4-induced hepatotoxicity is one of the best-documented cases for the participation of cytochrome P450 2E1 in a toxicologically important reductive reaction. The reduction of oxygen to superoxide and peroxide are also important reductive reactions of the enzyme and could be important in lipid peroxidation. However, the role of this reaction in vivo remains controversial.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537462     DOI: 10.1096/fasebj.6.2.1537462

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  96 in total

Review 1.  Targeting collagen expression in alcoholic liver disease.

Authors:  Kyle J Thompson; Iain H McKillop; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Cytochrome P-450 CYP2E1 knockout mice are protected against high-fat diet-induced obesity and insulin resistance.

Authors:  Haihong Zong; Michal Armoni; Chava Harel; Eddy Karnieli; Jeffrey E Pessin
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-12-20       Impact factor: 4.310

Review 3.  Nitric oxide and redox regulation in the liver: Part I. General considerations and redox biology in hepatitis.

Authors:  Diana L Diesen; Paul C Kuo
Journal:  J Surg Res       Date:  2009-10-09       Impact factor: 2.192

4.  Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population.

Authors:  R C Sobti; S Sharma; A Joshi; S K Jindal; A Janmeja
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

Review 5.  Does oxidative stress participate in the development of hepatocellular carcinoma?

Authors:  Yutaka Sasaki
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

Review 6.  Animal models of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Samantha R Fischbach; Gregory J Gores; Sumera Rizvi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-05       Impact factor: 5.187

Review 7.  Oxidative stress, unfolded protein response, and apoptosis in developmental toxicity.

Authors:  Allison Kupsco; Daniel Schlenk
Journal:  Int Rev Cell Mol Biol       Date:  2015-03-11       Impact factor: 6.813

8.  Alcohol Upregulation of CYP2A5: Role of Reactive Oxygen Species.

Authors:  Yongke Lu; Arthur I Cederbaum
Journal:  React Oxyg Species (Apex)       Date:  2016-03

Review 9.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.